Dependence of Acute Myeloid Leukemia on Adhesion within the Bone Marrow Microenvironment
Table 1
Clinical trials of combinations of adhesion inhibitors and chemotherapy for AML.
Title
Clinicaltrials.gov designation
Institution or sponsor
Study of plerixafor combined with cytarabine and daunorubicin in patients with newly diagnosed acute myeloid leukemia
NCT00990054
Multicenter-Genzyme-Sanofi
First in human study to determine the safety, tolerability, and preliminary effectiveness of MDX-1338 (BMS936564) in subjects with acute myelogenous leukemia (AML)
NCT01120457
Multicenter-Bristol-Myers Squibb
Granulocyte colony-stimulating factor (G-CSF) and plerixafor plus sorafenib for acute myelogenous leukemia (AML) with FLT3 mutations
NCT00943943
MD Anderson Cancer Center
Chemosensitization with plerixafor plus G-CSF in acute myeloid leukemia
NCT00906945
Washington University
IV plerixafor with mitoxantrone etoposide and cytarabine for acute myeloid leukemia (AML)
NCT01027923
Washington University
Plerixafor and clofarabine in frontline treatment of elderly patients with acute myelogenous leukemia (AML)
